UA112322U - Спосіб дотичного поетапного комплексного забору і дослідження матеріалу з кінцевого відділу уретри та уретральних лакун чоловіків за лазориком - Google Patents
Спосіб дотичного поетапного комплексного забору і дослідження матеріалу з кінцевого відділу уретри та уретральних лакун чоловіків за лазориком Download PDFInfo
- Publication number
- UA112322U UA112322U UAU201606494U UAU201606494U UA112322U UA 112322 U UA112322 U UA 112322U UA U201606494 U UAU201606494 U UA U201606494U UA U201606494 U UAU201606494 U UA U201606494U UA 112322 U UA112322 U UA 112322U
- Authority
- UA
- Ukraine
- Prior art keywords
- urethra
- sponges
- penis
- urethral
- smears
- Prior art date
Links
- 239000000463 material Substances 0.000 title claims abstract description 53
- 238000000034 method Methods 0.000 title claims abstract description 30
- 238000011835 investigation Methods 0.000 title 1
- 210000003708 urethra Anatomy 0.000 claims abstract description 102
- 210000003899 penis Anatomy 0.000 claims abstract description 44
- 235000015097 nutrients Nutrition 0.000 claims abstract description 22
- 229920000742 Cotton Polymers 0.000 claims abstract description 17
- 239000011521 glass Substances 0.000 claims abstract description 14
- 238000005070 sampling Methods 0.000 claims abstract description 11
- 210000004400 mucous membrane Anatomy 0.000 claims abstract description 10
- 230000028327 secretion Effects 0.000 claims abstract description 9
- 238000009331 sowing Methods 0.000 claims abstract description 9
- 210000004392 genitalia Anatomy 0.000 claims abstract description 7
- 238000000386 microscopy Methods 0.000 claims abstract description 6
- 210000003128 head Anatomy 0.000 claims description 25
- 229960000907 methylthioninium chloride Drugs 0.000 claims description 11
- 241000700605 Viruses Species 0.000 claims description 10
- 230000001580 bacterial effect Effects 0.000 claims description 10
- 238000003745 diagnosis Methods 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 230000001900 immune effect Effects 0.000 claims description 8
- 230000002906 microbiologic effect Effects 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 6
- 241000233866 Fungi Species 0.000 claims description 6
- 208000017064 TORCH syndrome Diseases 0.000 claims description 6
- 244000052769 pathogen Species 0.000 claims description 6
- 230000035945 sensitivity Effects 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 230000000844 anti-bacterial effect Effects 0.000 claims description 5
- 229940121375 antifungal agent Drugs 0.000 claims description 5
- 230000004069 differentiation Effects 0.000 claims description 5
- 230000004660 morphological change Effects 0.000 claims description 5
- 239000003429 antifungal agent Substances 0.000 claims description 4
- 230000009027 insemination Effects 0.000 claims description 3
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 claims 1
- 239000003973 paint Substances 0.000 abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 230000029142 excretion Effects 0.000 abstract 1
- 238000009595 pap smear Methods 0.000 abstract 1
- 238000011160 research Methods 0.000 description 18
- 210000002919 epithelial cell Anatomy 0.000 description 16
- 210000004907 gland Anatomy 0.000 description 14
- 238000010186 staining Methods 0.000 description 14
- 210000000265 leukocyte Anatomy 0.000 description 13
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 230000003902 lesion Effects 0.000 description 8
- 210000000981 epithelium Anatomy 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 241000207202 Gardnerella Species 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 210000003097 mucus Anatomy 0.000 description 5
- 239000006163 transport media Substances 0.000 description 5
- 208000000143 urethritis Diseases 0.000 description 5
- 210000002229 urogenital system Anatomy 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000003953 foreskin Anatomy 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000544 hyperemic effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- -1 cefatoxin Chemical compound 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002559 palpation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 241000606161 Chlamydia Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000006159 Sabouraud's agar Substances 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 230000008752 local inflammatory process Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012449 sabouraud dextrose agar Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201606494U UA112322U (xx) | 2016-06-13 | 2016-06-13 | Спосіб дотичного поетапного комплексного забору і дослідження матеріалу з кінцевого відділу уретри та уретральних лакун чоловіків за лазориком |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201606494U UA112322U (xx) | 2016-06-13 | 2016-06-13 | Спосіб дотичного поетапного комплексного забору і дослідження матеріалу з кінцевого відділу уретри та уретральних лакун чоловіків за лазориком |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA112322U true UA112322U (xx) | 2016-12-12 |
Family
ID=58044391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAU201606494U UA112322U (xx) | 2016-06-13 | 2016-06-13 | Спосіб дотичного поетапного комплексного забору і дослідження матеріалу з кінцевого відділу уретри та уретральних лакун чоловіків за лазориком |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA112322U (xx) |
-
2016
- 2016-06-13 UA UAU201606494U patent/UA112322U/uk unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fouts et al. | Trichomonas vaginalis: reevaluation of its clinical presentation and laboratory diagnosis | |
| Blackwell et al. | Clinic diagnosis of anaerobic vaginosis (non-specific vaginitis). A practical guide. | |
| Shingade et al. | Menstrual hygiene among married women: a hospital based cross-sectional study in an urban slum of Mumbai, India | |
| Catterall | Diagnosis of vaginal discharge. | |
| JP7236112B2 (ja) | Ｈｖｓ及びｐａｐスミアテスト装置 | |
| UA112322U (xx) | Спосіб дотичного поетапного комплексного забору і дослідження матеріалу з кінцевого відділу уретри та уретральних лакун чоловіків за лазориком | |
| UA118859C2 (uk) | Спосіб діагностики уражень сечостатевої системи чоловіків за лазориком | |
| De Jong | Medical Detection and Effects f the Sexual Abuse of Child ren | |
| ZIGAS | An evaluation of trichomoniasis in two ethnic groups in Papua New Guinea | |
| Kaimal et al. | Methods of specimen collection for the diagnosis of STIs | |
| Donald | Aetiology and investigation of vaginal discharge | |
| World Health Organization | Training of health staff in VIA, HPV detection test and cryotherapy-Trainees’ handbook | |
| RU2364340C1 (ru) | Способ забора биологического материала для микробиологического исследования микрофлоры влагалища | |
| Allen | Trichomonas vaginalis vaginitis | |
| RU2799581C1 (ru) | Зонд для забора биологического материала из полости матки | |
| Hanif et al. | VAGINAL DISCHARGE: FREQUENCY OF DIFFERENT ORGANISMS RESPONSIBLE FOR VAGINAL DISCHARGE | |
| Jishna et al. | Journal of Skin and Sexually Transmitted Diseases | |
| Rasimovich et al. | EVALUATION OF THE EFFECTIVENESS OF THE USE OF AUXILIARY TECHNIQUES IN THE DIAGNOSIS OF TRICHOMONAS INFECTION | |
| Peate | Chlamydia: Recognition and management | |
| Barlow | Sexually Transmitted Infections: The Facts | |
| Daniels et al. | Chlamydia | |
| Beller et al. | Gynecological History and Physical Examination | |
| Passos | Vulvovaginitis | |
| Watson | Gonorrhoea and its complications in the male & female | |
| Adler | Vaginal Discharge: Diagnosis |